Latest | Instant Finance & Market News_第102页 | NewTimeSpace

10:07

[ Samsung S\&P Gsci Crude Oil Er Futures Etf (03175.HK) Rises 3.11% in Morning Trade, Turnover at HKD 1.7320 Million ] NewTimeSpace News: As of August 31 at 10:08, Samsung S\&P Gsci Crude Oil Er Futures Etf (03175.HK) rose 3.11%, with a latest price of HKD 10.600.

Tag： Samsung S&P Gsci Crude Oil Er Futures Etf 03175.HK ETF

10:03

[ Boantong Technologies files for GEM listing on HKEX; IoT wireless communications and PCBA solutions provider offering over 160 specifications ] NewTimeSpace News: On 30 August 2026, Boantong Technologies Limited filed a listing application on the GEM of HKEX; the Company focuses on wireless modules, antennas and PCBA solutions with over 20 years of IoT wireless communications experience, covering consumer, industrial and energy electronics; it offers solutions in over 160 specifications serving more than 1,500 customers annually, with 11.4% year-on-year revenue growth between 2024 and 2025; major customers are located mainly in China, accounting for 89.4%-94.9% of total revenue in the recent two years and two half-year periods.

Tag： Boantong IPO GEM file a listing application

10:01

[ Chinaamc Hang Seng Tech Index Etf (03088.HK) Falls 1.53% in Morning Trade, AUM at HKD 1.532 Billion ] NewTimeSpace News: As of August 31 at 10:02, Chinaamc Hang Seng Tech Index Etf (03088.HK) fell 1.53%, with a latest price of HKD 5.785.

Tag： Chinaamc Hang Seng Tech Index Etf ETF 03088.HK

10:01

[ Ligent Technologies passes HKEX hearing; fifth-largest professional optical module maker globally with integrated optical chip capabilities ] NewTimeSpace News: On 30 August 2026, Ligent Technologies, Inc. passed the HKEX listing hearing; by 2025 global optical module revenue the Company ranked fifth among professional manufacturers (4.0% share) and third by China optical module revenue (10.1% share); the Company is among the first in China to mass-produce 800G/1.6T optical modules, has developed LPO/LRO optical modules and ELSFP light source modules, and self-develops DFB and EML laser chips; it holds 1,581 patents globally and has participated in the formulation of 61 industry standards.

Tag： Ligent Technologies IPO pass the listing hearing

09:55

[ Hailiang Co. files for HKEX listing; global leader in copper processing, with rapid growth in copper foil and AIDC thermal management ] NewTimeSpace News: On 30 August 2026, Zhejiang Hailiang Co., Ltd. filed a listing application with HKEX; the Company is a global supplier of copper-based products covering HVAC/industrial copper tubes, rods, bars and fittings, ultra-thin copper foil and AIDC liquid cooling components, with 23 production bases in Asia, Europe, North America and Africa as of 31 May 2026; in 2025 the Company ranked first globally in HVAC and industrial copper-processed product shipments and first in copper tube shipments for six consecutive years; 2025 revenue was RMB 83.3 billion, with lithium battery and PCB copper foil revenue up 102.5% year on year and net profit up 61.9% year on year.

Tag： Hailiang IPO file a listing application

09:55

[ CSOP STAR 50 Index ETF (03109.HK) Falls 2.28% in Morning Trade, Turnover at HKD 1.0541 Million ] NewTimeSpace News: As of August 31 at 09:56, CSOP STAR 50 Index ETF (03109.HK) fell 2.28%, with a latest price of HKD 15.890.

Tag： CSOP STAR 50 Index ETF 03109.HK ETF

09:51

[ Bangshun Pharma files for HKEX listing; two core products targeting JAK2 and BTK, focused on oncology and autoimmune innovative drugs ] NewTimeSpace News: On 30 August 2026, Hangzhou Bangshun Pharmaceutical Co., Ltd. filed a listing application with HKEX; incorporated in 2020, the Company focuses on innovative drugs for oncology and autoimmune diseases, with a pipeline comprising two core products — bezesertinib (a selective JAK2 inhibitor for MF/PV/ET) and CX1440 (a registration-stage BTK inhibitor for ITP/CU/AIHA) — plus five preclinical candidates; according to Frost & Sullivan, bezesertinib is among the first three approved domestic JAK inhibitors for MF in China and ranks first in China for PV and first globally for ET, while CX1440 ranks top three globally for ITP and top two globally for CU and AIHA.

Tag： Bangshun Pharma IPO file a listing application

09:48

[ XSKY files for HKEX listing; China's largest independent distributed AI storage solutions provider by 2025 installations ] NewTimeSpace News: On 30 August 2026, Beijing XSKY Technology Co., Ltd. filed a listing application with HKEX; by 2025 installations, the Company is China's largest independent distributed AI storage solutions provider with a 10.6% market share, offering data lake and training/inference storage solutions based on proprietary XSEA/XScale technologies, delivered as software or appliances; the Company turned profitable in 2025 with a profit of RMB 7.1 million for the year, recording a profit of RMB 0.3 million in H1 2026 versus a loss of RMB 10.5 million in H1 2025.

Tag： XSKY Tech IPO file a listing application

09:47

[ E Fund (HK) Solactive Global Gold Miner Select Index ETF (02824.HK) Falls 5.10% in Morning Trade, AUM at HKD 391 Million ] NewTimeSpace News: As of August 31 at 09:52, E Fund (HK) Solactive Global Gold Miner Select Index ETF (02824.HK) fell 5.10%, with a latest price of HKD 11.530.

Tag： E Fund (HK) Solactive Global Gold Miner Select Index ETF ETF 02824.HK

09:44

[ Exegenesis Bio files for HKEX listing; pipeline of nine gene therapy candidates with core products covering wAMD and SMA type 1 ] NewTimeSpace News: On 28 August 2026, Exegenesis Bio Inc. filed a listing application with HKEX; incorporated in 2019, the Company focuses on gene therapies for neurological and ophthalmic diseases with a pipeline of nine candidates; core product EXG102-031 (wAMD) completed the 52-week follow-up of its Phase IIa trial in China in May 2026 with Phase IIb/III expected in H2 2026, and its US Phase I is complete; core product EXG001-307 (SMA type 1) has completed all Phase I/II trials; key product EXG202 (wAMD/DME/RVO) obtained FDA IND in July 2025 in the US, aiming to bypass Phase I, and NMPA approval in August 2025 in China for a combined Phase I/II study.

Tag： Exegenesis Bio Inc.IPO file a listing application

09:34

[ Club Med Lifestyle Group files for HKEX listing; world's largest resort brand by 2025 turnover, operating 69 premium resorts globally ] NewTimeSpace News: On 28 August 2026, Club Med Lifestyle Group filed a listing application with HKEX; founded in 1950 as the pioneer of the premium all-inclusive resort industry, Club Med operates 69 premium resorts globally with a sales network spanning more than 40 countries and regions across six continents; according to CIC, by 2025 turnover it is the world's largest resort brand and, by number of resorts and turnover, the world's largest all-inclusive resort brand; in 2026 it was included in TIME's 100 Most Influential Companies, the only hotel and resort brand on the list that year.

Tag： Club Med Lifestyle IPO file a listing application

09:31

[ Frontera Therapeutics files for HKEX listing; rAAV gene therapy company focused on ophthalmology and cardiovascular diseases with six candidates ] NewTimeSpace News: On 28 August 2026, Frontera Therapeutics filed a listing application with HKEX; incorporated in 2019, the Company is a clinical-stage gene therapy company focused on ophthalmology and cardiovascular diseases, with a pipeline of six in-house developed rAAV gene therapy candidates, including core products FT-002 (XLRP) and FT-003 (nAMD and DME) and key product FT-001 (RPE65-related IRD); its patent portfolio comprises one Japanese patent and 29 patent applications, with US applications for FT-002 and FT-003 receiving notices of allowance in May and June 2026 respectively.

Tag： Frontera Therapeutics IPO file a listing application

09:14

[ Betta Pharmaceuticals files for HKEX listing; three first-in-class domestic targeted drugs commercialized, profitable for many consecutive years ] NewTimeSpace News: On 28 August 2026, Betta Pharmaceuticals Co., Ltd. filed a listing application with HKEX; the Company is a biopharmaceutical company operating across the full industry chain at the commercialization stage, profitable for many consecutive years since its first product launch in 2011; its commercialized products icotinib (Kaima'na, EGFR TKI), ensartinib (Beima'na, ALK TKI) and vorolanib (Fumeina, VEGFR/PDGFR inhibitor) are each the first domestic drug of their class approved in China or entering the global market; the Company has a pipeline of over ten clinical programs covering EGFR, ALK and other targets, also exploring breast cancer, renal cancer, hematological diseases and ophthalmology.

Tag： Betta Pharma IPO file a listing application

09:08

[ Tangji Medical files for HKEX listing; core product is China's first endoscopic weight-loss device, with high-growth EBMT market ] NewTimeSpace News: On 28 August 2026, Hangzhou Tangji Medical Technology Co., Ltd. filed a listing application with HKEX; incorporated in 2016, the Company focuses on the treatment and comprehensive management of metabolic diseases, with core product GBS being China's first medical device approved for the endoscopic treatment of obesity, and is expanding to lower-BMI indications, along with 13 pipeline products; according to Frost & Sullivan, China's obese population reached 233.7 million in 2025 and is expected to reach 329.8 million by 2034, and the China EBMT device market is projected to grow at a CAGR of 111.1% from RMB 32 million in 2025 to RMB 1,352 million in 2030.

Tag： Tangji Medical IPO file a listing application

09:03

[ ABBISKO-B (02256.HK): First patient dosed in Phase I trial of pan-KRAS inhibitor ABSK211, preclinically covering multiple KRAS alterations ] NewTimeSpace News: On 31 August 2026, ABBISKO-B (02256.HK) announced that the first patient has been dosed in the Phase I trial of ABSK211, an oral small-molecule pan-KRAS inhibitor developed by its subsidiary Abbisko, in patients with advanced solid tumors harboring KRAS alterations; preclinically, ABSK211 demonstrated broad-spectrum potent inhibition across G12D/G12C/G12S/G12V/G13D and wild-type amplification subtypes, with combination potential with PRMT5 inhibitors, cetuximab, immunotherapy and chemotherapy; it has received IND approvals from China's NMPA and the US FDA, with global clinical development advancing.

Tag： ABBISKO-B 02256.HK Clinical Trial

09:02

[ ETHK LABS INC.(01931.HK)2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 70.49 million, turned into a loss from a profit YoY ] NewTimeSpace (newtimespace.com) News,August 31, 2026, ETHK LABS INC.(01931.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 1.35 billion, increased by 6.63% YoY

Tag： ETHK LABS INC.01931.HK NewTimeSpace

09:02

[ LIAONING PORT(02880.HK)2026 Interim Report - Profit Attributable to Shareholders stood at CNY 884.91 million, YoY decrease of 7.41% ] NewTimeSpace (newtimespace.com) News,August 30, 2026, LIAONING PORT(02880.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 5.35 billion, decreased by 6.03% YoY

Tag： LIAONING PORT 02880.HK NewTimeSpace

09:02

[ ZGC TEC LEASING(01601.HK)2026 Interim Report - Profit Attributable to Shareholders stood at CNY 130.29 million, YoY decrease of 9.72% ] NewTimeSpace (newtimespace.com) News, August 28, 2026, ZGC TEC LEASING(01601.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 386.69 million, decreased by 7.37% YoY

Tag： ZGC TEC LEASING 01601.HK NewTimeSpace

09:02

[ PETROCHINA(00857.HK)2026 Interim Report - Profit Attributable to Shareholders stood at CNY 103.94 billion, YoY increase of 22.01% ] NewTimeSpace (newtimespace.com) News, August 30, 2026, PETROCHINA(00857.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 1527.49 billion, increased by 5.34% YoY

Tag： PETROCHINA 00857.HK NewTimeSpace

09:02

[ CHINA RES MIXC(01209.HK)2026 Interim Report - Profit Attributable to Shareholders stood at CNY 2.24 billion, YoY increase of 10.29% ] NewTimeSpace (newtimespace.com) News,August 31, 2026, CHINA RES MIXC(01209.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 9.22 billion, increased by 8.13% YoY

Tag： CHINA RES MIXC 01209.HK NewTimeSpace

Scan QR Code

Download App